Eurand Announces Proposed Public Offering of Ordinary Shares

AMSTERDAM, THE NETHERLANDS--(Marketwire - October 15, 2009) - Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the proposed sale of 8,500,000 ordinary shares in an underwritten public offering, subject to market and other conditions.

Of the 8,500,000 shares being offered, 2,000,000 are to be issued by Eurand and the remaining 6,500,000 are to be sold by certain selling stockholders. The selling stockholders will grant the underwriters an option to purchase an additional 1,275,000 ordinary shares at the public offering price to cover over-allotments, if any.

Deutsche Bank Securities and BofA Merrill Lynch are acting as joint book-running managers of the proposed offering. Thomas Weisel Partners and Cowen & Co. are acting as co-managers of the offering.

The offering may be made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus, when available, can be obtained from Deutsche Bank Securities Inc., by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com and from BofA Merrill Lynch, 4 World Financial Center, New York, 10080, attention: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.

Forward-Looking Statement

This release, and oral statements made with respect to information contained in this release, constitute forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. The words “expects”, “potentially”, “anticipates”, “could”, “calls for” and similar expressions also identify forward-looking statements. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.